Puma Biotechnology, Inc. PBYI R2K

Healthcare · Biotechnology · United States

https://www.pumabiotechnology.com

Company Profile ↓

$8.28

+140.00% 1Y

Mkt Cap$421.45M

P/E17.25

P/B2.90

52W High$8.28

52W Low$3.07

Book Value$2.52

EPS (TTM)$0.48

Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 21.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 27.6%.

Steady Revenue Expansion

Revenue has grown at a 30.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 17.2, below the sector median of 25.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.12.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $228.37M (-0.9% YoY); net profit $31.11M.
Trailing 12 Months Year-on-year growth — revenue -2.6%, earnings +2.8%.
5-Year Trend Long-term compounding — revenue CAGR 30.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	30.18%
1 Year:	-2.60%

Compounded Profit Growth

5 Years:	-
1 Year:	2.75%

Stock Price Performance

1 Year:	+140.00%
6 Months:	+35.52%
3 Months:	+9.38%
1 Month:	+14.52%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 100% of range

$3.07 $8.28

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)61.72 · Neutral

Price Performance

1M+14.52%

3M+9.38%

6M+35.52%

1Y+140.00%

Valuation vs Sector

P/E of 17.25 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 21.6%.
Healthy ROCE of 27.6%.
Compounding revenue at 30.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

17.25

Industry PE

25.41

Forward P/E

23.66

PEG Ratio

Book Value

$2.52

Price to Book

2.90

P/S

1.64

EV/EBITDA

7.29

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

30.18%

Profit 5Y

Revenue (YoY)

-2.60%

Earnings (YoY)

2.75%

Profitability & Returns

ROCE

27.62%

ROE

21.62%

ROA

9.48%

Profit Margin

10.73%

Op Margin

-8.54%

Gross Margin

74.46%

EPS (Latest Qtr)

$-0.07

EPS (TTM)

$0.48

Balance Sheet & Liquidity

Debt/Equity

0.12

Quick Ratio

2.14

Current Ratio

2.38

Debt

$15.95M

Total Assets

$192.70M

Current Assets

$162.69M

Working Capital

$81.43M

Ownership

Promoter Holding

15.49%

Chg in Prom Hold

0.12%

FII / Inst Holding

75.02%

Chg in FII Hold

-2.51%

Financial Snapshot

Enterprise Value

$421.45M

Total Revenue (TTM)

$227.18M

EBITDA

$39.41M

Free Cash Flow

$44.09M

Operating Cash Flow

$53.61M

Shares Outstanding

50.90M

Gross Margin

74.46%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PBYI Puma Biotechnology, Inc. R2K	8.28	17.25	$421.45M	0.00%	27.62%	21.62%	30.18%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	6.08M	21.61M	66.52M	50.77M	62.63M	71.08M	99.07M	53.92M	56.35M	62.92M	51.22M	70.58M	50.75M	52.56M	98.17M	53.38M	46.24M	45.74M	59.52M	57.10M	52.77M	54.57M	56.12M	43.77M	47.08M	-	-	46.01M	52.44M	54.48M	75.45M	44.81M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.56M	12.30M	12.17M	23.13M	10.42M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35.45M	40.13M	42.30M	52.33M	34.39M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.47M	33.50M	32.73M	35.22M	38.22M
Operating Income	-60.73M	-	-71.25M	-66.48M	-66.00M	-	-73.20M	-78.18M	-77.44M	-	-23.39M	-41.44M	-11.28M	-	9.85M	-25.78M	-14.45M	-	-14.25M	7.13M	-12.13M	-	20.15M	-16.63M	-8.95M	-747.00K	12.06M	2.39M	4.37M	4.89M	8.59M	-2.30M	-2.18M	-	-	3.98M	6.64M	9.57M	17.11M	-3.83M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.24M	10.77M	13.45M	20.88M	-112.00K
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.18M	1.84M	1.49M	1.12M	731.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.27M	6.17M	9.24M	17.11M	-3.43M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	293.00K	310.00K	399.00K	3.67M	326.00K
Net Income	-60.42M	-61.72M	-70.97M	-66.60M	-65.78M	-72.66M	-72.86M	-77.83M	-77.18M	-64.08M	-24.34M	-44.34M	-14.20M	-30.69M	-10.09M	-37.42M	-16.89M	-11.20M	-16.93M	3.40M	-31.46M	-14.99M	16.53M	-5.11M	-44.67M	-3.40M	9.37M	-360.00K	1.40M	2.13M	5.80M	-4.82M	-4.53M	-	-	2.97M	5.86M	8.84M	13.44M	-3.75M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.97	-	-	-0.43	0.08	-0.79	-0.38	0.40	-0.13	-1.09	-0.08	0.21	-0.01	0.03	0.05	0.12	-0.10	-0.09	-	-	0.06	0.12	0.17	0.26	-0.07
R&D Expense	51.92M	-	60.21M	54.22M	51.98M	-	54.80M	53.25M	49.50M	-	46.92M	43.24M	36.36M	-	35.73M	36.85M	30.03M	-	25.45M	24.69M	23.34M	-	20.23M	18.64M	18.84M	15.24M	11.97M	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	27.68M	250.99M	272.26M	225.11M	253.16M	228.03M	235.64M	230.47M	228.37M
Operating Income	-10.16M	-74.45M	-54.83M	-142.28M	-240.28M	-276.60M	-292.39M	-94.66M	-39.05M	-30.40M	1.29M	23.72M	32.64M	30.97M	37.30M
Net Income	-10.23M	-74.35M	-54.66M	-141.97M	-239.28M	-276.01M	-291.95M	-113.58M	-75.59M	-59.99M	-29.13M	2.00K	21.59M	30.28M	31.11M
Diluted EPS	-	-	-	-	-	-	-	-	-	-1.52	-0.72	0.00	0.45	0.62	0.61
R&D Expense	826.00K	49.64M	45.05M	122.92M	208.47M	222.80M	207.81M	164.85M	132.85M	97.65M	71.87M	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2010	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	55.40M	151.70M	104.37M	162.76M	239.84M	252.79M	165.53M	259.12M	234.91M	244.22M	-	222.06M	230.53M	213.33M	216.30M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	134.28M	156.19M	147.66M	162.69M
Cash & Equivalents	0	0	53.38M	137.41M	43.04M	38.54M	31.57M	194.49M	81.70M	108.42M	60.04M	85.29M	-	76.20M	84.58M	69.22M	29.64M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	4.53M	7.08M	8.72M	5.51M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	40.35M	47.84M	32.01M	53.65M
Total Liabilities	-	-	1.03M	22.79M	20.39M	45.71M	33.84M	42.97M	112.22M	224.82M	217.44M	250.17M	-	200.45M	177.09M	121.21M	85.96M
Current Liabilities	-	-	587.00K	21.70M	19.27M	44.44M	32.44M	37.46M	58.34M	67.11M	90.84M	114.25M	-	77.48M	99.38M	96.11M	81.25M
Long Term Debt	-	-	-	-	-	-	-	-	48.48M	151.89M	94.96M	84.03M	97.09M	98.31M	65.66M	21.72M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	114.28M	111.49M	74.08M	28.55M
Total Equity	-	-	54.37M	128.91M	83.99M	117.05M	206.01M	209.82M	53.30M	34.31M	17.46M	-5.95M	-	21.61M	53.44M	92.12M	130.34M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	46.35M	47.65M	49.11M	50.41M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.82M	-44.01M	-55.05M	-	-	-141.69M	-172.47M	-24.11M	22.38M	773.00K	20.65M	-15.83M	27.01M	38.92M	41.80M
Investing Cash Flow	-1.75M	-1.22M	-41.53M	-	-	142.19M	-15.44M	-57.62M	5.16M	33.40M	-10.88M	7.10M	-19.12M	-20.44M	-36.19M
Financing Cash Flow	56.95M	129.26M	2.21M	-	-	162.43M	75.11M	108.45M	-67.07M	-9.93M	-31.93M	12.22M	0	-33.85M	-45.20M
Capital Expenditure	-253.33K	-	-624.00K	-1.10M	-1.00M	-4.29M	-431.00K	-439.00K	-306.00K	-46.00K	-0	-0	-140.00K	-56.00K	-71.00K
Free Cash Flow	-2.08M	-	-55.67M	-	-	-145.98M	-172.90M	-24.54M	22.07M	727.00K	20.65M	-15.83M	26.87M	38.86M	41.73M

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-1,056.1%	-37.7%	-14.3%	-13.5%	0.5%	10.4%	13.9%	13.4%	16.3%
Net Margin %	-	-	-	-	-	-	-1,054.6%	-45.3%	-27.8%	-26.7%	-11.5%	0.0%	9.2%	13.1%	13.6%
ROE %	-18.8%	-57.7%	-65.1%	-121.3%	-116.2%	-131.5%	-547.7%	-331.1%	-432.9%	1,008.1%	-	0.0%	40.4%	32.9%	23.9%
ROCE %	-18.5%	-57.3%	-64.4%	-120.2%	-115.9%	-128.5%	-272.8%	-49.3%	-27.1%	-23.4%	-	16.4%	24.9%	26.4%	27.6%

Shareholding Pattern

Insiders

15.49%

Institutions

75.02%

Public Float

88.77%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Acorn Capital Advisors, LLC	8.12%	4.13M	$34.29M
2	Blackrock Inc.	7.07%	3.60M	$29.87M
3	Acadian Asset Management. LLC	4.01%	2.04M	$16.95M
4	Renaissance Technologies, LLC	3.82%	1.94M	$16.12M
5	American Century Companies Inc	3.76%	1.92M	$15.91M
6	Vanguard Capital Management LLC	3.57%	1.82M	$15.09M
7	Vanguard Portfolio Management LLC	3.41%	1.73M	$14.40M
8	Millennium Management Llc	2.90%	1.48M	$12.26M
9	Dimensional Fund Advisors LP	2.82%	1.44M	$11.92M
10	LSV Asset Management	2.32%	1.18M	$9.82M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PBYI

Google News hu, 09 Jul 2026

Insider Sale: President and CEO of $PBYI Sells 44,058 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQa3VHNjNNTlBWUmNNTG4yMkRtUUNMQTBpV1hLOHp2OFpFandGRFc2Q0FJQzNocl9DVEpTQmExY3N3TjFfZjFvSUNnbEhkaDJCWU5FeV82Qnh6MVhrb0ZqWWhIanRaQjBqYWIwYUlTSWliX3dvYkYzT2htaFdBd1hOZWZWd180T2tFX1dlVG…

Google News hu, 09 Jul 2026

PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNaGJkdUxwU1RWYzdWV0k5TmZ3ZmFhTUpRejN3MFc1a2s4NXpFMl9vWU1IUENQTnREV0tuQ0tyd0s3RGIxVW9KNHh3Sk9KalNkaVZGQWlJSGpaZkVfR29mdW5Zc0pIZVk0aDR5M25SVUlfbmRsbDBiRVZmb0VjRE40dDZhQkprQ2I0Wkd0M1…

Google News Fri, 27 Feb 2026

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1xdWxkbVNmOFdQek45bE43MEluWFQ4dFFObnp3Yl9mVG5ocC1yV3E1NnZFdFQwaGh6NTllTW83eHVwdHJ0NEtCa3hoTXBzR3drajU1bzdnUnRrNnM5alBQWThCSDY2ZXlfeF8tSHI2cHpjTEozaVVUSFZGTXhMZw?oc=5" target="_blan…

Google News Fri, 03 Jul 2026

PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFBLUFNLOF9wV3hhSGtaQ3QzeDllNEZpQlVOV29QZk1qX3FleGRmTy1UNXlvVnpWRDJBWnZvTlNmWlo5a1JjcVFjdk5BelhadGo4ZDJsZFJJVXpwNGc?oc=5" target="_blank">PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:P…

Google News Fri, 08 May 2026

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMVRQWGlHM0Ytd1B5em1xN2lxS25MZlRaZ0RMR1QxVkY4YjBFSEc4NnVWekdiT0ZlSVJsSkxWQmRKU0RuMkticnpibUpVVEN4VzYxQ2swOXI1QlBaS21qVm1SZXRxdEswZTFMRmxIVU5vMFdVY0l0NHliTjVVb1YtYzdkakM3anNYd01rVm…

Google News Sun, 28 Jun 2026

PBYI Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE0wbldpRHdjcEM4NWhReUQ0eXdWVm5FczdxRHpIZHdyT1luVFZCSmdoalhSZENSMXNabFFZbXY0bFhnZzJVWEtONFZJNlFCRXNWUTNNOXNpcmlKZm9hTVBUSmpRQjlVQldmal9pbHVidWVDWGtIbXRqaVl3?oc=5" target="_blank">PBY…

PBYI — Frequently Asked Questions

What is the current share price of Puma Biotechnology, Inc. (PBYI)?

As of 2026-07-14 21:23 PDT, Puma Biotechnology, Inc. (PBYI) trades at $8.28 on NasdaqGS. Its 52-week range is $3.07 to $8.28.

What is the market capitalisation of PBYI?

Puma Biotechnology, Inc. (PBYI) has a market capitalisation of $421.45M on NasdaqGS.

What is the P/E ratio of PBYI?

PBYI trades at a trailing price-to-earnings (P/E) ratio of 17.25. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.90.

What is the return on equity (ROE) of PBYI?

PBYI has a return on equity (ROE) of 21.62%. Its return on capital employed (ROCE) is 27.62%.

Is PBYI a good stock to buy?

This page provides a data-driven analysis of Puma Biotechnology, Inc. (PBYI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Puma Biotechnology, Inc. PBYI R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Insider Sale: President and CEO of $PBYI Sells 44,058 Shares - Quiver Quantitative

PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan - Stock Titan

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - Yahoo Finance

PBYI News | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Zacks Investment Research

PBYI Forecast — Price Target — Prediction for 2027 - TradingView

PBYI — Frequently Asked Questions

What is the current share price of Puma Biotechnology, Inc. (PBYI)?

What is the market capitalisation of PBYI?

What is the P/E ratio of PBYI?

What is the return on equity (ROE) of PBYI?

Is PBYI a good stock to buy?

Explore More